Ronald M. Lombardi, the Chief Executive Officer of Prestige Consumer Healthcare Inc. (NYSE:PBH), recently executed significant stock transactions, according to the latest SEC filings. On November 18, Lombardi sold a total of 82,237 shares of the company's common stock, generating approximately $6.8 million. The shares were sold at prices ranging from $81.50 to $82.67 per share.
In addition to the sales, Lombardi also exercised stock options, acquiring 82,237 shares at prices between $56.11 and $57.18 per share. Following these transactions, Lombardi's direct ownership stands at 320,952 shares. These moves come as part of Lombardi's ongoing management of his equity holdings in the company.
In other recent news, Prestige Consumer Healthcare reported mixed results for its second quarter of 2025. The company's sales slightly declined to $284 million, with notable challenges faced by the Clear Eyes brand due to supply chain issues. However, an increase in earnings per share to $1.09 and a generation of $68 million in free cash flow were recorded. The decline was offset by international growth, particularly with the Hydralyte brand and Canadian portfolio.
The company also provided guidance for the fiscal year, expecting revenues to be between $1.125 billion and $1.140 billion, and an adjusted EPS forecast of $4.40 to $4.46. Despite supply chain challenges, management expressed confidence in the brand strength of Clear Eyes and Summer's Eve for future growth.
These are among the recent developments for Prestige Consumer Healthcare, which remains committed to capital deployment strategies, including share repurchases and exploring merger and acquisition opportunities.
InvestingPro Insights
Recent transactions by Prestige Consumer Healthcare Inc.'s (NYSE:PBH) CEO Ronald M. Lombardi align with several key financial indicators and market trends for the company. According to InvestingPro data, PBH's stock is currently trading near its 52-week high, with a price at 98.43% of its peak. This aligns with the strong return the stock has shown over the last three months, as highlighted by InvestingPro Tips.
The company's P/E ratio stands at 19.8, suggesting a moderate valuation relative to earnings. This could be seen as attractive, considering PBH's solid financial position. InvestingPro Tips indicate that the company's liquid assets exceed short-term obligations, pointing to a healthy balance sheet.
Interestingly, while Lombardi has sold shares, InvestingPro Tips reveal that PBH offers a high shareholder yield, which typically combines dividends, share repurchases, and debt reduction. This suggests that the company is returning value to shareholders through means other than dividends, as PBH does not currently pay a dividend.
For investors seeking more comprehensive analysis, InvestingPro offers 11 additional tips for PBH, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.